Skip NavigationSkip to Content
Return Return to Search Results

Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling

  1. Author:
    Klumpp-Thomas, Carleen
    Kalish, Heather
    Drew,Matt
    Hunsberger, Sally
    Snead,Kelly
    Fay, Michael P.
    Mehalko,Jennifer
    Shunmugavel, Anandakumar
    Wall,Vanessa
    Frank,Peter
    Denson,John-Paul
    Hong,Min
    Gulten,Gulcin
    Messing,Simon
    Hicks, Jennifer
    Michael, Sam
    Gillette,Bill
    Hall, Matthew D.
    Memoli, Matthew J.
    Esposito,Dom
    Sadtler, Kaitlyn

  2. Author Address

    Natl Ctr Adv Translat Sci, NIH, Rockville, MD 20850 USA.Natl Inst Biomed Imaging & Bioengn, Sect Immunoengn, NIH, Bethesda, MD 20894 USA.Natl Inst Biomed Imaging & Bioengn, NIH, Trans NIH Shared Resource Biomed Engn & Phys Sci, Bethesda, MD 20894 USA.NCI RAS Initiat, Frederick Natl Lab Canc Res, Prot Express Lab, Frederick, MD 21702 USA.NIAID, Biostat Res Branch, NIH, Bethesda, MD 20894 USA.NIAID, LID Clin Studies Unit, Div Intramural Res, Lab Infect Dis,NIH, Bethesda, MD 20894 USA.
    1. Year: 2021
    2. Date: Jan 4
    3. Epub Date: 2021 Mar 30
  2. Journal: Nature Communications
  3. NATURE RESEARCH,
    1. 12
    2. 1
  5. Type of Article: Article
  6. Article Number: ARTN 113
  7. ISSN: 2041-1723
  1. Abstract:

    The extent of SARS-CoV-2 infection throughout the United States population is currently unknown. High quality serology is key to avoiding medically costly diagnostic errors, as well as to assuring properly informed public health decisions. Here, we present an optimized ELISA-based serology protocol, from antigen production to data analyses, that helps define thresholds for IgG and IgM seropositivity with high specificities. Validation of this protocol is performed using traditionally collected serum as well as dried blood on mail-in blood sampling kits. Archival (pre-2019) samples are used as negative controls, and convalescent, PCR-diagnosed COVID-19 patient samples serve as positive controls. Using this protocol, minimal cross-reactivity is observed for the spike proteins of MERS, SARS1, OC43 and HKU1 viruses, and no cross reactivity is observed with anti-influenza A H1N1 HAI. Our protocol may thus help provide standardized, population-based data on the extent of SARS-CoV-2 seropositivity, immunity and infection. Understanding the infection parameters and host responses against SARS-CoV-2 require data from large cohorts using standardized methods. Here, the authors optimize a serum ELISA protocol that has minimal cross-reactivity and flexible sample collection workflow in an attempt to standardize data generation and help inform on COVID-19 pandemic and immunity.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1038/s41467-020-20383-x
  3. PMID: 33397956
  4. View record in Web of Science®
  5. WOS: 000665639800004

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel